Chi Sheng Pharma & Biotech Co (ROCO:4111) Beginning Cash Position: NT$419 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4111 Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
82 GF Score
Price NT$30.15
GF Value NT$33.09
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chi Sheng Pharma & Biotech Co Beginning Cash Position?

Chi Sheng Pharma & Biotech Co ROCO:4111 +0.33% 82 Beginning Cash Position is NT$419 Mil as of Jun. 2026. GuruFocus rates ROCO:4111 with a GF Score™ of 82/100 and a GF Value™ of NT$33.09 (Fairly Valued). The stock has 1 warning sign investors should review.

Chi Sheng Pharma & Biotech Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$419 Mil.

Chi Sheng Pharma & Biotech Co's quarterly Beginning Cash Position increased from Dec. 2025 (NT$422 Mil) to Mar. 2026 (NT$444 Mil) but then declined from Mar. 2026 (NT$444 Mil) to Jun. 2026 (NT$419 Mil).

Chi Sheng Pharma & Biotech Co's annual Beginning Cash Position declined from Dec. 2023 (NT$456 Mil) to Dec. 2024 (NT$381 Mil) and declined from Dec. 2024 (NT$381 Mil) to Dec. 2025 (NT$336 Mil).

Chi Sheng Pharma & Biotech Co Beginning Cash Position Related Terms

Chi Sheng Pharma & Biotech Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Chi Sheng Pharma & Biotech Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chi Sheng Pharma & Biotech Co Beginning Cash Position Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 335.80 252.27 456.25 381.05 336.19

Chi Sheng Pharma & Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 321.32 322.83 421.85 443.91 419.20
ROCO:4111
82GF Score
Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chi Sheng Pharma & Biotech Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$419 Mil mean?
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a Beginning Cash Position of NT$419 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Chi Sheng Pharma & Biotech Co and its competitors.
Is Chi Sheng Pharma & Biotech Co's Beginning Cash Position too high?
Chi Sheng Pharma & Biotech Co's current Beginning Cash Position is NT$419 Mil. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's Beginning Cash Position compare to ISRG and BDX?
Chi Sheng Pharma & Biotech Co's Beginning Cash Position of NT$419 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. Chi Sheng Pharma & Biotech Co's current Beginning Cash Position is NT$419 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.09, compared to a current price of NT$30.15 — trading 8.9% below its estimated fair value. The current Beginning Cash Position is NT$419 Mil. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current Beginning Cash Position is NT$419 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?

Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued. The current stock price of NT$30.15 is trading 8.9% below its estimated GF Value™ of NT$33.09. GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.

Key valuation signals for ROCO:4111:

  • Beginning Cash Position: NT$419 Mil
  • GF Value™: NT$33.09 vs. price of NT$30.15 (8.9% below fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chi Sheng Pharma & Biotech Co Business Description

Address No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
82GF Score

Get the complete analysis for ROCO:4111

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.15
Price
NT$33.09
GF Value